|
|
|
|
|
|
|
|
|
|
Note: excerpt - Avastin + chemo
"Genentech and Roche are also conducting a randomized double-blind placebo-controlled Phase II trial in advanced ovarian cancer in a maintenance setting, which is evaluating the ability of GDC-0449 to slow the time to recurrence of cancer in patients whose disease is in complete remission, by impeding the residual cancer cells' ability to grow. Roche has indicated that results from this study are expected during the second half of 2010."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.